Therapeutic reinvigoration of tumor-specific T cells has greatly improved clinical outcome in
cancer. Nevertheless, many patients still do not achieve durable benefit. Recent evidence …

In cancer, T cells become dysfunctional owing to persistent antigen exposure. Dysfunctional
T cells are characterized by reduced proliferative capacity, decreased effector function, and …

Targeting immune checkpoints such as programmed cell death protein 1 (PD1),
programmed cell death 1 ligand 1 (PDL1) and cytotoxic T lymphocyte antigen 4 (CTLA4) has …

The immune system deploys a multitude of innate and adaptive mechanisms not only to
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …

Purpose: Urelumab is an agonist antibody to CD137 with potential application as an
immuno-oncology therapeutic. Data were analyzed to assess safety, tolerability, and …

The immune system is capable of recognizing tumors and eliminates many early malignant
cells. However, tumors evolve to evade immune attack, and the tumor microenvironment is …

Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory
programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the …

Immune checkpoint inhibitors demonstrate clinical activity in many tumor types, however,
only a fraction of patients benefit. Combining CD137 agonists with these inhibitors increases …

Tumor-associated or-infiltrating lymphocytes (TALs or TILs) co-express multiple immune
inhibitory receptors that contribute to immune suppression in the ovarian tumor …

Ovarian cancer is the most lethal of all gynecological cancers, and there is an urgent unmet
need to develop new therapies. Epithelial ovarian cancer (EOC) is characterized by an …